439 related articles for article (PubMed ID: 33916348)
1. Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond.
Park R; Da Silva LL; Saeed A
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916348
[TBL] [Abstract][Full Text] [Related]
2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
3. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
4. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
[TBL] [Abstract][Full Text] [Related]
5. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
6. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
7. Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy.
Liu S; Zhang Y; Lin Y; Wang P; Pan Y
Front Immunol; 2022; 13():981527. PubMed ID: 36119063
[TBL] [Abstract][Full Text] [Related]
8. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability
Jin Z; Yoon HH
J Gastrointest Oncol; 2016 Oct; 7(5):771-788. PubMed ID: 27747091
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability.
Montella M; Sabetta R; Ronchi A; De Sio M; Arcaniolo D; De Vita F; Tirino G; Caputo A; D'Antonio A; Fiorentino F; Facchini G; Lauro GD; Perdonà S; Ventriglia J; Aquino G; Feroce F; Borges Dos Reis R; Neder L; Brunelli M; Franco R; Zito Marino F
Front Med (Lausanne); 2022; 9():874213. PubMed ID: 35592855
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging immunotherapeutic approaches for biliary tract cancers.
Yuan ZG; Zeng TM; Tao CJ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
12. Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden.
Sagredou S; Dalezis P; Papadopoulou E; Voura M; Deligiorgi MV; Nikolaou M; Panayiotidis MI; Nasioulas G; Sarli V; Trafalis DT
Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34203761
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
Duffy MJ; Crown J
Clin Chem; 2019 Oct; 65(10):1228-1238. PubMed ID: 31315901
[TBL] [Abstract][Full Text] [Related]
15. Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC.
Bie F; Tian H; Sun N; Zang R; Zhang M; Song P; Liu L; Peng Y; Bai G; Zhou B; Gao S
Front Oncol; 2022; 12():769124. PubMed ID: 35223466
[TBL] [Abstract][Full Text] [Related]
16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
17. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
18. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
Masetti M; Lindinger M; Lorenzen S
Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
[TBL] [Abstract][Full Text] [Related]
19. BAT26 Only Microsatellite Instability with High Tumor Mutation Burden-A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression.
Kang SY; Kim DG; Kim KM
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142641
[TBL] [Abstract][Full Text] [Related]
20. How I treat MSI cancers with advanced disease.
Kok M; Chalabi M; Haanen J
ESMO Open; 2019; 4(Suppl 2):e000511. PubMed ID: 31231574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
